NasdaqCM:CLDXBiotechs
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run
Celldex Therapeutics stock has delivered a strong 59.5% return over the past year, yet the current valuation checks and market multiples point to a price that leans on the expensive side rather than a clear bargain.
Over the past 12 months, Celldex Therapeutics has returned 59.5%, which puts extra focus on whether recent gains are already pricing in much of the expected progress.
For a clinical stage biotech like Celldex Therapeutics, the prospect of advancing its pipeline can support higher...